

09-27-01

A

09/24/01

Jc945 U.S. PTO

UTILITY PATENT  
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: P-204.00CON

Page 1 of 2

Title: ALPHA 1-ANTITRYPSIN PREPARATION AND  
METHOD FOR THE PRODUCTION THEREOF

Express Mail Label No.: EL800474590US

## APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

INVENTORS: Erwin Mattes, H. Peter Matthiessen

1. ☒ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)2. ☒ Specification [Total Pages 3. ☐ Drawing(s) (35 USC §113) [Total Pages (Fig. 1- ) 4. ☒ Signed Declaration [Total Pages a. ☐ Newly executed (original or copy)b. ☒ Copy from a prior application (37 CFR §1.63(d))

(Note Box 5 below)

i. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)

5. ☐ Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.6. ☐ Nucleotide and/or Amino Acid Sequence Submissiona. ☐ Computer Readable Copy  
b. ☐ Paper Copy (identical to computer copy)  
c. ☐ Statement Verifying identity of above copies7. ☐ Assignment Papers (cover sheet & document(s))8. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney9. ☐ English Translation Document

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/445,59010. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations11. ☒ Preliminary Amendment filed 12/10/99 and preliminary Amendment filed herewith.12. ☒ Return Receipt Postcard (MPEP 503)13. ☐ Small Entity Statement(s)14. ☐ Certified Copy of Priority Documents (s)15a. ☐ Cancel in the application original claims before calculating the filing fee15b. ☒ Amend the specification by inserting before the first line the sentence: --This is a X Continuation,          Divisional,          Continuation-in-part, of application 09/445,590, filed 03/13/00.15c. ☒ I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number 09/445,590, filed 03/13/00 and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any Patent issuing thereon.15d. ☐ Other:15e. ☐ OtherJc921 U.S. PTO  
09/24/01  
09/24/01

UTILITY PATENT  
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: P-204.00CON

Page 2 of 2

Title: ALPHA 1-ANTITRYPSIN PREPARATION AND  
METHOD FOR THE PRODUCTION THEREOF


Express Mail Label No.: EL800474590US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	10-20 =	0	X \$ 18 =	\$ .00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1-3 =	0	X \$ 80 =	\$ .00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 270 =	\$ .00
				BASIC FEE (37 CFR §1.16(a))	\$710.00
				TOTAL =	\$710.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket P-204.00CON).  
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
- b. ☒ Fees required under 37 CFR §1.17
- c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350
SIGNATURE	
DATE	September 24, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation  
P.O. Box 15210  
Irvine, California 92614  
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL800474590US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on September 24, 2001.

By:



Diane Branham

Form 2000-10-15-0000